Multistage delivery of chemotherapeutic nanoparticles for breast cancer treatment

Cancer Letters

Volumn 334, Issue 2, 2013, Pages 245-252

  Blanco, Elvin ^a   Sangai, Takafumi ^b   Hsiao, Angela ^a   Ferrati, Silvia ^a   Bai, Litao ^a   Liu, Xuewu ^a   Meric Bernstam, Funda ^b   Ferrari, Mauro ^a  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer nanomedicine; Mesoporous silicon particles; Multistage drug delivery; Paclitaxel; Polymer micelles

Indexed keywords

COPOLYMER; CREMOPHOR; ETHYLENE GLYCOL EPSILON CAPROLACTONE COPOLYMER; MESOPOROUS SILICON PARTICLE; NANOPARTICLE; PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MCF-7 CELLS; MICE; MICE, NUDE; MICELLES; NANOPARTICLES; RANDOM ALLOCATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 84878251881     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.07.027     Document Type: Article

References (50)

1. Duncan R., Gaspar R. Nanomedicine(s) under the microscope. Mol. Pharm. 2011, 8:2101-2141.
2. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 2005, 5:161-171.
3. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2:751-760.
4. Hamilton A., Biganzoli L., Coleman R., Mauriac L., Hennebert P., Awada A., Nooij M., Beex L., Piccart M., Van Hoorebeeck I., Bruning P., de Valeriola D. EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European organization for research and treatment of cancer. Ann. Oncol. 2002, 13:910-918.
5. van Dalen C., Michiels E.M., Caron H.N., Kremer L.C. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst. Rev. 2010, CD005006.
6. Celia C., Cosco D., Paolino D., Fresta M. Gemcitabine-loaded innovative nanocarriers vs. GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity. Exp. Opin. Drug Deliv. 2011, 8:1609-1629.
7. Licciardi M., Paolino D., Celia C., Giammona G., Cavallaro G., Fresta M. Folate-targeted supramolecular vesicular aggregates based on polyaspartyl-hydrazide copolymers for the selective delivery of antitumoral drugs. Biomaterials 2010, 31:7340-7354.
8. Lee C.C., MacKay J.A., Frechet J.M., Szoka F.C. Designing dendrimers for biological applications. Nat. Biotechnol. 2005, 23:1517-1526.
9. Kataoka K., Harada A., Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv. Drug Deliv. Rev. 2001, 47:113-131.
10. Cabral H., Nishiyama N., Kataoka K. Supramolecular nanodevices: from design validation to theranostic nanomedicine. Acc. Chem. Res. 2011, 44:999-1008.
11. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005, 4:145-160.
12. Gabizon A., Shmeeda H., Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin. Pharmacokinet. 2003, 42:419-436.
13. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 2001, 41:189-207.
14. Ferrari M. Frontiers in cancer nanomedicine: directing mass transport through biological barriers. Trends Biotechnol. 2010, 28:181-188.
15. Michor F., Liphardt J., Ferrari M., Widom J. What does physics have to do with cancer?. Nat. Rev. Cancer 2011, 11:657-670.
16. Tasciotti E., Liu X., Bhavane R., Plant K., Leonard A.D., Price B.K., Cheng M.M., Decuzzi P., Tour J.M., Robertson F., Ferrari M. Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat. Nanotechnol. 2008, 3:151-157.
17. Ananta J.S., Godin B., Sethi R., Moriggi L., Liu X., Serda R.E., Krishnamurthy R., Muthupillai R., Bolskar R.D., Helm L., Ferrari M., Wilson L.J., Decuzzi P. Geometrical confinement of gadolinium-based contrast agents in nanoporous particles enhances T(1) contrast. Nat. Nanotechnol. 2010, 5:815-821.
18. Tanaka T., Mangala L.S., Vivas-Mejia P.E., Nieves-Alicea R., Mann A.P., Mora E., Han H.D., Shahzad M.M., Liu X., Bhavane R., Gu J., Fakhoury J.R., Chiappini C., Lu C., Matsuo K., Godin B., Stone R.L., Nick A.M., Lopez-Berestein G., Sood A.K., Ferrari M. Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res. 2010, 70:3687-3696.
19. Decuzzi P., Pasqualini R., Arap W., Ferrari M. Intravascular delivery of particulate systems: does geometry really matter?. Pharm. Res. 2009, 26:235-243.
20. Decuzzi P., Ferrari M. Design maps for nanoparticles targeting the diseased microvasculature. Biomaterials 2008, 29:377-384.
21. Chiappini C., Tasciotti E., Fakhoury J.R., Fine D., Pullan L., Wang Y.C., Fu L., Liu X., Ferrari M. Tailored porous silicon microparticles: fabrication and properties. Chemphyschem 2010, 11:1029-1035.
22. van de Ven A.L., Kim P., Haley O., Fakhoury J.R., Adriani G., Schmulen J., Moloney P., Hussain F., Ferrari M., Liu X., Yun S.H., Decuzzi P. Rapid tumoritropic accumulation of systemically injected plateloid particles and their biodistribution. J. Control Release 2012, 158:148-155.
23. Blanco E., Bey E.A., Dong Y., Weinberg B.D., Sutton D.M., Boothman D.A., Gao J. Beta-lapachone-containing PEG-PLA polymer micelles as novel nanotherapeutics against NQO1-overexpressing tumor cells. J. Control Release 2007, 122:365-374.
24. Shin H.C., Alani A.W., Cho H., Bae Y., Kolesar J.M., Kwon G.S. A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs. Mol. Pharm. 2011, 8:1257-1265.
25. Moreno A., Akcakanat A., Munsell M.F., Soni A., Yao J.C., Meric-Bernstam F. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr. Relat. Cancer 2008, 15:257-266.
26. Mondesire W.H., Jian W., Zhang H., Ensor J., Hung M.C., Mills G.B., Meric-Bernstam F. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin. Cancer Res. 2004, 10:7031-7042.
27. Savic R., Luo L., Eisenberg A., Maysinger D. Micellar nanocontainers distribute to defined cytoplasmic organelles. Science 2003, 300:615-618.
28. Ferrati S., Mack A., Chiappini C., Liu X., Bean A.J., Ferrari M., Serda R.E. Intracellular trafficking of silicon particles and logic-embedded vectors. Nanoscale 2010, 2:1512-1520.
29. Apfel S.C., Lipton R.B., Arezzo J.C., Kessler J.A. Nerve growth factor prevents toxic neuropathy in mice. Ann. Neurol. 1991, 29:87-90.
30. Bayraktar S., Gonzalez-Angulo A.M., Lei X., Buzdar A.U., Valero V., Melhem-Bertrandt A., Kuerer H.M., Hortobagyi G.N., Sahin A.A., Meric-Bernstam F. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancer 2011.
31. Shajahan A.N., Wang A., Decker M., Minshall R.D., Liu M.C., Clarke R. Caveolin-1 tyrosine phosphorylation enhances paclitaxel-mediated cytotoxicity. J. Biol. Chem. 2007, 282:5934-5943.
32. Liu Y., Zhang B., Yan B. Enabling anticancer therapeutics by nanoparticle carriers: the delivery of Paclitaxel. Int. J. Mol. Sci. 2011, 12:4395-4413.
33. Gelderblom H., Verweij J., Nooter K., Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer 2001, 37:1590-1598.
34. Weiss R.B., Donehower R.C., Wiernik P.H., Ohnuma T., Gralla R.J., Trump D.L., Baker J.R., Van Echo D.A., Von Hoff D.D., Leyland-Jones B. Hypersensitivity reactions from taxol. J. Clin. Oncol. 1990, 8:1263-1268.
35. Ibrahim N.K., Samuels B., Page R., Doval D., Patel K.M., Rao S.C., Nair M.K., Bhar P., Desai N., Hortobagyi G.N. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J. Clin. Oncol. 2005, 23:6019-6026.
36. Kim T.Y., Kim D.W., Chung J.Y., Shin S.G., Kim S.C., Heo D.S., Kim N.K., Bang Y.J. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin. Cancer Res. 2004, 10:3708-3716.
37. Kim S., Shi Y., Kim J.Y., Park K., Cheng J.X. Overcoming the barriers in micellar drug delivery: loading efficiency, in vivo stability, and micelle-cell interaction. Exp. Opin. Drug Deliv. 2010, 7:49-62.
38. Savic R., Azzam T., Eisenberg A., Maysinger D. Assessment of the integrity of poly(caprolactone)-b-poly(ethylene oxide) micelles under biological conditions: a fluorogenic-based approach. Langmuir 2006, 22:3570-3578.
39. Burt H.M., Zhang X., Toleikis P., Embree L., Hunter W.L. Development of copolymers of poly(d,l-lactide) and methoxypolyethylene glycol as micellar carriers of paclitaxel. Colloids Surf. B: Biointerfaces 1999, 16:161-171.
40. Chen H., Kim S., He W., Wang H., Low P.S., Park K., Cheng J.X. Fast release of lipophilic agents from circulating PEG-PDLLA micelles revealed by in vivo forster resonance energy transfer imaging. Langmuir 2008, 24:5213-5217.
41. Zhang K., Loong S.L., Connor S., Yu S.W., Tan S.Y., Ng R.T., Lee K.M., Canham L., Chow P.K. Complete tumor response following intratumoral 32P BioSilicon on human hepatocellular and pancreatic carcinoma xenografts in nude mice. Clin. Cancer Res. 2005, 11:7532-7537.
42. Serda R.E., Mack A., van de Ven A.L., Ferrati S., Dunner K., Godin B., Chiappini C., Landry M., Brousseau L., Liu X., Bean A.J., Ferrari M. Logic-embedded vectors for intracellular partitioning, endosomal escape, and exocytosis of nanoparticles. Small 2010, 6:2691-2700.
43. Torchilin V.P. Targeted polymeric micelles for delivery of poorly soluble drugs. Cell Mol. Life Sci. 2004, 61:2549-2559.
44. Williams C., Bryant A. Short versus long duration infusions of paclitaxel for any advanced adenocarcinoma. Cochrane Database Syst. Rev. 2011, CD003911.
45. ten Tije A.J., Verweij J., Loos W.J., Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin. Pharmacokinet. 2003, 42:665-685.
46. Lee S.Y., Ferrari M., Decuzzi P. Shaping nano-/micro-particles for enhanced vascular interaction in laminar flows. Nanotechnology 2009, 20:495101.
47. Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., Hawkins M., O'Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 2005, 23:7794-7803.
48. de Hoon J.P., Veeck J., Vriens B.E., Calon T.G., van Engeland M., Tjan-Heijnen V.C. Taxane resistance in breast cancer: a closed HER2 circuit?. Biochim. Biophys. Acta 1825, 2012:197-206.
49. Lee K.S., Chung H.C., Im S.A., Park Y.H., Kim C.S., Kim S.B., Rha S.Y., Lee M.Y., Ro J. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res. Treat. 2008, 108:241-250.
50. Slowing I.I., Vivero-Escoto J.L., Wu C.W., Lin V.S. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv. Drug Deliv. Rev. 2008, 60:1278-1288.